{{Infobox drug
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477861573
| IUPAC_name = (3''R'',5''R'')-7-[2-(4-Fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid 
| image = Atorvastatin2DCSD.svg
| width = 300
| image2 = Atorvastatin-3D-balls.png
| width2 = 250

<!--Clinical data-->
| tradename = Lipitor, Atorva
| Drugs.com = {{drugs.com|monograph|lipitor}}
| MedlinePlus = a600045
| licence_US = Atorvastatin
| pregnancy_AU = D
| pregnancy_US = X
| legal_AU = S4
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = 口服
| DailyMedID = 42465

<!--Pharmacokinetic data-->
| bioavailability = 12%
| metabolism = [[肝脏|肝脏]] - [[CYP3A4|CYP3A4]]
| elimination_half-life = 14小时
| excretion = [[胆汁|胆汁]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 134523-00-5
| ATC_prefix = C10
| ATC_suffix = AA05
| PubChem = 60823
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = APRD00055
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 54810
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = A0JWA85V8F
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07474
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 39548
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1487
| PDB_ligand = 117
| IUPHAR_ligand = 2949

<!--Chemical data-->
 | C=33 | H=35 | F=1 | N=2| O=5 
| molecular_weight = 558.64
| smiles = O=C(O)C[C@H](O)C[C@H](O)CCn2c(c(c(c2c1ccc(F)cc1)c3ccccc3)C(=O)Nc4ccccc4)C(C)C
| InChI = 1/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
| InChIKey = XUKUURHRXDUEBC-KAYWLYCHBX
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XUKUURHRXDUEBC-KAYWLYCHSA-N
}}
{{medical}}
'''阿托伐他汀'''（{{lang-en|'''Atorvastatin'''}}），商品名为'''立普妥'''（Lipitor），是降低[[血液|血液]][[胆固醇|胆固醇]]水平的常见药物。由[[辉瑞公司|辉瑞公司]]制造。<ref>http://www.lipitor.com/ {{Wayback|url=http://www.lipitor.com/ |date=20190516095927 }} Pfizer product promotion page (Liptor)</ref>。它是一种[[他汀类|他汀类]]药物，用于降低血液中的胆固醇。它还可稳定血液斑块和预防[[中风|中风]]。类似于所有他汀類藥物，阿托伐他汀通過抑制[[肝|肝]]組織中，一種對膽固醇製造起關鍵作用的[[酵素|酵素]]——[[羟甲基戊二酸单酰辅酶A还原酶|羟甲基戊二酸单酰辅酶A还原酶]]（HMG-CoA reductase），以減少體內製造膽固醇。

阿托伐他汀於1985年由布魯斯·羅斯-帕克-戴維斯華納-蘭伯特公司（Bruce Roth of Parke-Davis Warner-Lambert Company）首次合成（現為[[輝瑞|輝瑞公司]]/Pfizer），是製藥歷史上銷售最好的藥物。它自1996年被[[美國食品藥品監督管理局|美國食品藥品監督管理局]]批准以來，累計銷售額超過1,250億美元<ref>http://www.crainsnewyork.com/article/20111228/HEALTH_CARE/111229902 {{Wayback|url=http://www.crainsnewyork.com/article/20111228/HEALTH_CARE/111229902 |date=20180307041114 }} Crain's New York Business. 2011-12-28.</ref>，並連續保持此銷售冠軍紀錄達十年<ref>http://www.nytimes.com/2011/11/12/health/plan-would-delay-sales-of-generic-for-lipitor.html {{Wayback|url=http://www.nytimes.com/2011/11/12/health/plan-would-delay-sales-of-generic-for-lipitor.html |date=20210506222432 }} New York Times.</ref>。通用阿托伐他汀，由{{le|沃森製藥公司|Watson Pharmaceuticals}}和[[蘭伯西實驗室|蘭伯西實驗室]]製造，並於2011年11月30日開始於[[美國|美國]]上市。

==主治==
阿托伐他汀的主要用途是治療[[血脂異常|血脂異常]]和預防[[心血管疾病|心血管疾病]]。<ref name="AHFS">[http://www.drugs.com/monograph/atorvastatin-calcium.html Atorvastatin Calcium] {{Wayback|url=http://www.drugs.com/monograph/atorvastatin-calcium.html |date=20200810032559 }} Drugs.com. Retrieved 3 April 2011.</ref>需要注意的是病人應在透過運動、減重與加強飲食等日常生活管理各方面都沒法改善膽固醇水平的情形下，才服用阿托伐他汀。<ref name="AHFS"/>

===血脂異常===
*[[高膽固醇血症|高膽固醇血症]]（Hypercholesterolemia，包括子家族和非家族），[[混合性高血脂|混合性高血脂]]（弗雷德里克森IIa和IIb型）以降低總[[膽固醇|膽固醇]]、[[低密度脂蛋白|低密度脂蛋白-C]]、[[apo-B|apo-B]]、[[甘油三酯|甘油三酯]]和[[C反應蛋白|C反應蛋白]]水平但增加[[高密度脂蛋白|高密度脂蛋白]]的水平。<ref name="pmid12915827">{{cite journal | author = McCrindle BW, Ose L, Marais AD | title = Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial | journal = J. Pediatr. | volume = 143 | issue = 1 | pages = 74–80 |date=July 2003 | pmid = 12915827 | doi = 10.1016/S0022-3476(03)00186-0 | url =https://archive.org/details/sim_journal-of-pediatrics_2003-07_143_1/page/74}}</ref><ref name="pmid15325833">{{cite journal | author = Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH | title = Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial | journal = Lancet | volume = 364 | issue = 9435 | pages = 685–96 | year = 2004 | pmid = 15325833 | doi = 10.1016/S0140-6736(04)16895-5 }}</ref><ref name="pmid16084850">{{cite journal | author = Backman JT, Luurila H, Neuvonen M, Neuvonen PJ | title = Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites | url = https://archive.org/details/sim_clinical-pharmacology-and-therapeutics_2005-08_78_2/page/154 | journal = Clin. Pharmacol. Ther. | volume = 78 | issue = 2 | pages = 154–67 |date=August 2005 | pmid = 16084850 | doi = 10.1016/j.clpt.2005.04.007 }}</ref><ref name="pmid16765141">{{cite journal | author = Hermann M, Bogsrud MP, Molden E, Asberg A, Mohebi BU, Ose L, Retterstøl K | title = Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy | url = https://archive.org/details/sim_clinical-pharmacology-and-therapeutics_2006-06_79_6/page/532 | journal = Clin. Pharmacol. Ther. | volume = 79 | issue = 6 | pages = 532–9 |date=June 2006 | pmid = 16765141 | doi = 10.1016/j.clpt.2006.02.014 }}</ref><ref name="pmid16908955">{{cite journal | author = Ozaki K, Kubo T, Imaki R, Shinagawa H, Fukaya H, Ohtaki K, Ozaki S, Izumi T, Aizawa Y | title = The anti-atherosclerotic effects of lipid lowering with atorvastatin in patients with hypercholesterolemia | journal = J. Atheroscler. Thromb. | volume = 13 | issue = 4 | pages = 216–9 | date = August 2006 | pmid = 16908955 | doi = 10.5551/jat.13.216 | url = http://www.jstage.jst.go.jp/article/jat/13/4/216/_pdf | access-date = 2014-02-16 | archive-date = 2019-12-05 | archive-url = https://web.archive.org/web/20191205223029/https://www.jstage.jst.go.jp/sblogin/jat/13/4/216/-char/en?sourceurl=%2Farticle%2Fjat%2F13%2F4%2F216%2F_pdf&backurl=%2Fbrowse%2F-char%2Fen | dead-url = yes }}</ref>
*小兒雜合子家族性高膽固醇血症<ref name="pmid12915827" />
*純合子家族性高膽固醇血症<ref name="pmid12915827" /><ref name="pmid9301631">{{cite journal | author = Marais AD, Firth JC, Bateman ME, Byrnes P, Martens C, Mountney J | title = Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia | url = https://archive.org/details/sim_arteriosclerosis-thrombosis-and-vascular-biology_1997-08_17_8/page/1527 | journal = Arterioscler. Thromb. Vasc. Biol. | volume = 17 | issue = 8 | pages = 1527–31 |date=August 1997 | pmid = 9301631 | doi =10.1161/01.ATV.17.8.1527 }}</ref>
*高甘油三酯血症（弗雷德里克森IV型）
*初級血β脂蛋白異常（弗雷德里克森III型）
*混合型[[高脂血症|高脂血症]]<ref>McCrindle BW, Ose L, Marais AD (July 2003). "Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial". J. Pediatr. 143 (1): 74–80. DOI:10.1016/S0022-3476(03)00186-0. PMID 12915827.</ref><ref>Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM (April 2006). "Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial". Journal of the American Medical Association 295 (13): 1556–65. DOI:10.1001/jama.295.13.jpc60002. PMID 16533939.</ref><ref name="#1">Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM (May 1995). "Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor". Arterioscler. Thromb. Vasc. Biol. 15 (5): 678–82. DOI:10.1161/01.ATV.15.5.678. PMID 7749881.</ref><ref name="#1"/><ref>Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM (January 1996). "Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia". Journal of the American Medical Association 275 (2): 128–33. DOI:10.1001/jama.275.2.128. PMID 8531308.</ref><ref>Marais AD, Firth JC, Bateman ME, Byrnes P, Martens C, Mountney J (August 1997). "Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia". Arterioscler. Thromb. Vasc. Biol. 17 (8): 1527–31. DOI:10.1161/01.ATV.17.8.1527. PMID 9301631.</ref><ref>Rossi S, ed. (2006). Australian medicines handbook 2006. Adelaide, S. Aust: Australian Medicines Handbook Pty Ltd. ISBN 978-0-9757919-2-9.</ref>

===心血管疾病===
*預防[[冠狀動脈性心臟病|冠狀動脈性心臟病]]，預防[[心肌梗死|心肌梗死]]、[[中風|中風]]、不穩定[[心絞痛|心絞痛]]<ref name="pmid12686036">{{cite journal | author = Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J | title = Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial | journal = Lancet | volume = 361 | issue = 9364 | pages = 1149–58 |date=April 2003 | pmid = 12686036 | doi = 10.1016/S0140-6736(03)12948-0 | url = }}</ref><ref name="pmid12829554">{{cite journal | author = Law MR, Wald NJ, Rudnicka AR | title = Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis | journal = BMJ | volume = 326 | issue = 7404 | pages = 1423 |date=June 2003 | pmid = 12829554 | pmc = 162260 | doi = 10.1136/bmj.326.7404.1423 }}</ref>和{{le|血運重建|Revascularization}}。<ref name="Wilson_2008">{{cite journal | author = Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB | title = Prediction of coronary heart disease using risk factor categories | journal = Circulation | volume = 97 | issue = 18 | pages = 1837–47 | date = May 1998 | pmid = 9603539 | doi = 10.1161/01.CIR.97.18.1837 | url = http://circ.ahajournals.org/content/97/18/1837.full.pdf | access-date = 2014-02-16 | archive-date = 2011-09-19 | archive-url = https://web.archive.org/web/20110919174522/http://circ.ahajournals.org/content/97/18/1837.full.pdf | dead-url = no }}</ref><ref name="pmid9514454">{{cite journal | author = Jones P, Kafonek S, Laurora I, Hunninghake D | title = Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) | journal = American Journal of Cardiology | volume = 81 | issue = 5 | pages = 582–7 |date=March 1998 | pmid = 9514454 | doi = 10.1016/S0002-9149(97)00965-X }}</ref>
*預防II型糖尿病患者[[心肌梗死|心肌梗死]]和[[中風|中風]]。<ref>Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J (April 2003). "Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial". Lancet 361 (9364): 1149–58. DOI:10.1016/S0140-6736(03)12948-0. PMID 12686036.</ref><ref>Law MR, Wald NJ, Rudnicka AR (June 2003). "Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis". BMJ 326 (7404): 1423. DOI:10.1136/bmj.326.7404.1423. PMC 162260. PMID 12829554.</ref><ref>Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (May 1998). "Prediction of coronary heart disease using risk factor categories". Circulation 97 (18): 1837–47. DOI:10.1161/01.CIR.97.18.1837. PMID 9603539.</ref><ref>Jones P, Kafonek S, Laurora I, Hunninghake D (March 1998). "Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)". American Journal of Cardiology 81 (5): 582–7. DOI:10.1016/S0002-9149(97)00965-X. PMID 9514454.</ref><ref>Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH (2004). "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial". Lancet 364 (9435): 685–96. DOI:10.1016/S0140-6736(04)16895-5.</ref><ref>eil HA, DeMicco DA, Luo D, Betteridge DJ, Colhoun HM, Durrington PN, Livingstone SJ, Fuller JH, Hitman GA (November 2006). "Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS)". Diabetes Care 29 (11): 2378–84. DOI:10.2337/dc06-0872.</ref><ref>Gentile S, Turco S, Guarino G, Sasso CF, Amodio M, Magliano P, Salvatore T, Corigliano G, Agrusta M, De Simone G, Gaeta I, Oliviero B, Torella R (December 2000). "Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia". Diabetes Obes Metab</ref>

伴隨治療的注意事項：可和膽汁酸樹脂（[[離子交換樹脂|離子交換樹脂]]）相結合。不建議結合{{tsl|en|Fibrates|貝特類}}（Fibrate）藥物治療，    因為增加與肌肉損傷相關的不良反應的風險<ref name="uspi_lipitor.pdf">[http://www.pfizer.com/files/products/uspi_lipitor.pdf Lipitor: Prescribing Information] {{Wayback|url=http://www.pfizer.com/files/products/uspi_lipitor.pdf |date=20110506053711 }}. Pfizer. June 2009.</ref>。根據患者年齡，藥物劑量必須調整，降低肝功能不全。

==禁忌==
*活性肝病：{{le|膽汁淤積|Cholestasis}}、[[肝性腦病|肝性腦病]]、[[肝炎|肝炎]]、[[黃疸|黃疸]]
*原因不明的[[天冬氨酸氨基转移酶|天冬氨酸氨基转移酶]]（AST）或[[谷丙转氨酶|谷丙转氨酶]]（ALT）水平上升
*[[懷孕|懷孕]]
*[[母乳|母乳]]餵養

服用阿托伐他汀期間必須注意有某些情況下可能出現[[橫紋肌溶解症|橫紋肌溶解症]]，一種可引起{{le|肌红蛋白尿症|Myoglobinuria}}並導致急性[[腎衰竭|腎衰竭]]的併發症。如果被懷疑或診斷為橫紋肌溶解症，須立即停止阿托伐他汀治療<ref>Hermann M, Bogsrud MP, Molden E, Asberg A, Mohebi BU, Ose L, Retterstøl K (June 2006). "Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy". Clin. Pharmacol. Ther. 79 (6): 532–9. DOI:10.1016/j.clpt.2006.02.014. PMID 16765141.</ref>。但實驗顯示，阿托伐他汀可能起到保護腎功能的作用<ref>Williams D, Feely J (2002). "Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors". Clin Pharmacokinet 41 (5): 343–70. DOI:10.2165/00003088-200241050-00003. PMID 12036392.</ref>。另外，如果病人[[肌酸激酶|肌酸激酶]]（Creatine kinase，CK）的水平明顯升高和懷疑有{{le|肌病|Myopathy}}，也應停止使用阿托伐他汀。當與[[環孢素|環孢素]]、貝特類（Fibrate）藥物、[[紅黴素|紅黴素]]、[[烟酸|烟酸]]或[[唑|唑]]類[[抗真菌药|抗真菌药]]共同給藥有可能增加導致肌病的風險。<ref name="uspi_lipitor.pdf" />

在[[懷孕|懷孕]]期間是絕對禁止使用阿托伐他汀的，因為膽固醇是[[胎兒|胎兒]]發育的必須生物合成途徑，也包括[[類固醇|類固醇]]和[[細胞膜|細胞膜]]生成。另外也不建議餵哺[[母乳|母乳]]者服用此藥，因為通過老鼠的實驗表明阿托伐他汀可能會進入人類的乳汁分泌。<ref name="uspi_lipitor.pdf" />

==副作用==
阿托伐他汀最嚴重副作用為[[肌酸激酶|肌酸激酶]]（CK）升高導致的肌病和橫紋肌溶解症，雖然發生機會低於1%。<ref name="AMH_2006">{{cite book | editor = Rossi S | title = Australian medicines handbook 2006 | publisher = Australian Medicines Handbook Pty Ltd | location = Adelaide, S. Aust | year = 2006 | pages = | isbn = 0-9757919-2-3 | oclc = | doi = | accessdate = }}</ref><ref name="uspi_lipitor.pdf" />[[頭痛|頭痛]]是最常見的副作用，發生在10%的患者上。

其他副作用（發生機率在1–10%之間）包括：[[無力|無力]]、[[失眠|失眠]]和[[頭暈|頭暈]]、[[胸部疼痛|胸部疼痛]]和[[外週性水腫|外週性水腫]]、[[皮疹|皮疹]]、[[腹痛|腹痛]]、[[便秘|便秘]]、[[腹瀉|腹瀉]]、[[消化不良|消化不良]]、[[屁|胃腸脹氣]]、[[噁心|噁心]]、[[泌尿道感染|泌尿道感染]]、[[關節痛|關節痛]]、[[肌肉痛|肌肉痛]]、[[背痛|背痛]]、[[關節炎|關節炎]]、[[鼻竇炎|鼻竇炎]]、[[咽炎|咽炎]]、[[支氣管炎|支氣管炎]]、[[鼻炎|鼻炎]]、感染、[[流感|流感]]樣綜合徵和[[過敏|過敏]]性反應。<ref name="uspi_lipitor.pdf" />

小部分服用本藥和／或其它他汀類藥物病者曾引致失憶，特別是女性。因膽固醇的合成，是正常的神經元功能所必需的。但據輝瑞公司的臨床試驗，“膽固清沒有和失憶之間有因果關係。<ref name="#2">Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM (July 2003). "Statin-associated memory loss: analysis of 60 case reports and review of the literature". Pharmacotherapy 23 (7): 871–80. DOI:10.1592/phco.23.7.871.32720. PMID 12885101.</ref><ref>The side effects of statins: Heart healthy and head harmful?". Michael O'Riordan. HeartWire. 12 February 2008. Retrieved 22 October 2010</ref><ref>O'Riordan M (2010-10-22). "The side effects of statins: Heart healthy and head harmful?". The Wall Street Journal. Retrieved 2010-10-24.</ref>

在少數情況下，谷丙转氨酶（ALT）和天冬氨酸氨基转移酶（AST）水平會升高。<ref name="#3">Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, Greco AV, Littarru GP (March 1993). "Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study". J Clin Pharmacol 33 (3): 226–9. PMID 8463436.</ref>。

有報告指出高劑量阿托伐他汀能使血糖控制惡化。<ref name="pmid20507274">{{cite journal | author = Kostapanos MS, Liamis GL, Milionis HJ, Elisaf MS | title = Do statins beneficially or adversely affect glucose homeostasis? | journal = Curr Vasc Pharmacol | volume = 8 | issue = 5 | pages = 612–31 |date=September 2010 | pmid = 20507274 | doi = 10.2174/157016110792006879 }}</ref>

===藥物和食物的相互作用===
此藥物和{{link-en|安妥明|Clofibrate}}（Clofibrate）、[[非諾貝特|非諾貝特]]（Fenofibrate）、{{le|吉非貝齊|Gemfibrozil}}（Gemfibrozil）（一些治療高膽固醇血症藥物）有相互作用，可增加引致肌病和[[橫紋肌溶解症|橫紋肌溶解症]]風險。<ref name="pmid8463436">{{cite journal | author = Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, Greco AV, Littarru GP | title = Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study | url = https://archive.org/details/sim_journal-of-clinical-pharmacology_1993-03_33_3/page/226 | journal = J Clin Pharmacol | volume = 33 | issue = 3 | pages = 226–9 |date=March 1993 | pmid = 8463436 | doi =10.1002/j.1552-4604.1993.tb03948.x }}</ref><ref name="pmid18158710">{{cite journal | author = Steiner G | title = Atherosclerosis in type 2 diabetes: a role for fibrate therapy? | journal = Diab Vasc Dis Res | volume = 4 | issue = 4 | pages = 368–74 |date=December 2007 | pmid = 18158710 | doi = 10.3132/dvdr.2007.067 | url = }}</ref>

和CYP3A4抑制劑（[[伊曲康唑|伊曲康唑]]，泰利和[[伏立康唑|伏立康唑]]）共同用藥，可能會導致不良反應。和CYP3A4誘導劑（波生坦，磷苯妥英鈉，苯妥英）聯合用藥，可能減少阿托伐他汀的血液濃度。[[烟酸|烟酸]]也被證明增加肌病或橫紋肌溶解症的風險。他汀也能令其他藥物（如[[華法林|華法林]]或[[地高辛|地高辛]]）的濃度發生改變。補充[[維生素D|維生素D]]可降低阿托伐他汀和[[活性代謝物|活性代謝物]]濃度。

[[葡萄柚|葡萄柚]]汁是腸道CYP3A4的抑制劑，[[葡萄柚汁|葡萄柚汁]]與阿托伐他汀共服可能會導致{{le|Cmax|Cmax_(pharmacology)}}和AUC增加，從而導致不良反應或藥物過量並產生毒性。<ref name="#3"/><ref name="#2"/><ref>"The side effects of statins: Heart healthy and head harmful?". Michael O'Riordan. HeartWire. 12 February 2008. Retrieved 22 October 2010</ref><ref>http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228 {{Wayback|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228 |date=20100615010348 }} U.S. National Library of Medicine.</ref>

==作用機理==
阿托伐他汀是[[羟甲基戊二酸单酰辅酶A还原酶|HMG-CoA還原酶]]的競爭性抑制劑，這與其他他汀類藥物相似，但不同的是本藥為一個完全人工合成的[[化合物|化合物]]。 HMG-CoA還原酶催化還原[[甲羟戊酸途径|3-羥基-3-甲基-輔酶A]]（HMG-COA）成為[[甲羟戊酸|甲羟戊酸]]，這是[[肝臟|肝臟]]膽固醇生物合成的[[速率控制步驟|速率控制步驟]]（rate-limiting step）。通過抑制這種酵素，降低[[从头合成|从头合成]]膽固醇，增加[[肝細胞|肝細胞]]上的[[低密度脂蛋白受體|低密度脂蛋白受體]]（[[LDL受體|LDL受體]]），增加肝細胞對低密度脂蛋白的吸收，降低血液中的低密度脂蛋白膽固醇量。像其他他汀類藥物，阿托伐他汀也降低血液[[三酸甘油酯|三酸甘油酯]]水平，並略有增加高密度脂蛋白膽固醇水平。

==藥代動力學==
口服阿托伐他汀吸收迅速，最大血藥濃度1至2小時。該藥物的絕對[[生物利用度|生物利用度]]約為14%。阿托伐他汀通過[[腸道|腸道]]時經歷[[首过效应|首过效应]]，這是此藥的生物利用度低的主要原因。儘管當阿托伐他汀與食物一起服用時，其降低血液LDL（[[低密度脂蛋白|低密度脂蛋白]]）的效用並沒因此減少，但與食物共服，藥物{{le|Cmax|Cmax_(pharmacology)}}（吸收率）減少25%，AUC（吸收程度）減少9%；而夜間服藥Cmax（吸收率）和AUC（吸收程度）減少30%，但都不會影響阿托伐他汀的療效。

阿托伐他汀的[[蛋白結合率|蛋白結合率]]高（≥98%），阿托伐他汀代謝主要通過[[細胞色素P450|細胞色素P450]]-3A4羥基形成。以激活鄰位類羥基化代謝物和[[β-氧化|β-氧化]]代謝物。前者對全身的HMG-CoA還原酶運作起關鍵效用。鄰羥基代謝物進一步透過{{le|葡糖醛酸代謝作用|Glucuronidation}}代謝。細胞色素P450的抑制劑和诱导剂分別能增加或減少此藥的血藥濃度，這已被一項以[[紅黴素|紅黴素]]（一種已知的細胞色素P450抑制劑）與阿托伐他汀為對象的實驗室試驗中被驗證。

阿托伐他汀主要是經肝[[膽汁|膽汁]]排泄，阿托伐他汀在尿液中回收的不到2%，沒有進入{{le|肠肝循环|Enterohepatic circulation}}。阿托伐他汀消除半衰期約14小時。值得注意的是，HMG-CoA還原酶抑制活性有半衰期20至30小時，這被認為是與活性代謝產物有關。阿托伐他汀也是腸道{{le|P-糖蛋白|P-glycoprotein}}外排轉運，在藥物正在腸臟被吸收時被泵回腸腔中。<ref name="pmid12036392">{{cite journal | author = Williams D, Feely J | title = Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors | journal = Clin Pharmacokinet | volume = 41 | issue = 5 | pages = 343–70 | year = 2002 | pmid = 12036392 | doi = 10.2165/00003088-200241050-00003 }}</ref>

[[肝臟|肝]]功能不全患者，血藥濃度受到肝臟疾病顯著影響。與A-末期肝病患者Cmax和AUC增加4倍。B超末期肝病患者的Cmax增加16倍、AUC增加11倍。老年患者（65歲以上）藥代動力學表現與年輕成年人不同，老年患者的AUC和Cmax值分別提高40%和30%；而健康長者對藥物反應較理想，故可能只需處方較低劑量予此人群。<ref name="uspi_lipitor.pdf"/><ref>Villa J, Pratley RE (June 2010). "Ezetimibe/simvastatin or atorvastatin for the treatment of hypercholesterolemia in patients with the metabolic syndrome: the VYMET study". Curr. Diab. Rep. 10 (3): 173–5. DOI:10.1007/s11892-010-0107-5. PMID 20425579.</ref><ref>McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P (July 2010). "Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets". Int. J. Clin. Pract. 64 (8): 1052–61. DOI:10.1111/j.1742-1241.2010.02429.x. PMID 20487050.</ref>

==藥理學==
阿托伐他汀一些[[基因多態性|基因多態性]]（Genetic polymorphism）已被發現與本藥不良副作用的發生率較高有關。這種現象被懷疑與[[血漿|血漿]]中的藥理活性代謝產物增加有關，如阿托伐他汀內酯和P-Hydroxyatorvastatin。對於較可能誘發不良副作用的潛在患者，可使用特定的色譜技術對阿托伐他汀及其活性代謝物進行監測。<ref>Deshmukh HA, Colhoun HM, Johnson T, McKeigue PM, Betteridge DJ, Durrington PN, Fuller JH, Livingstone S, Charlton-Menys V, Neil A, Poulter N, Sever P, Shields DC, Stanton AV, Chatterjee A, Hyde C, Calle RA, Demicco DA, Trompet S, Postmus I, Ford I, Jukema JW, Caulfield M, Hitman GA (May 2012). "Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)". J Lipid Res 53 (5): 1000–1011. DOI:10.1194/jlr.P021113. PMID 22368281.</ref>

==配方==
[[File:Atorvastatin40mg.jpg|200px]]
阿托伐他汀鈣片由[[輝瑞|輝瑞]]公司銷售。藥片為白色、橢圓形的薄膜包衣片。輝瑞公司還與其他藥物打包結合，如Caduet。輝瑞公司建議服食者不要將藥片一分為二。

==參考==
{{reflist|2}}

==延伸閱讀==
{{refbegin|35em}}
* {{cite web | url = http://labeling.pfizer.com/ShowLabeling.aspx?id=587 | title = Highlights of prescribing information | date = 2009-06-01 | format = pdf | work = Lipitor (atorvastatin calcium) Tablets for oral administration | publisher = Pfizer | accessdate = 2011-10-26 | archive-date = 2011-05-06 | archive-url = https://web.archive.org/web/20110506053711/http://www.pfizer.com/files/products/uspi_lipitor.pdf | dead-url = no }}
* {{cite journal | author = Maggon K | title = Best-selling human medicines 2002-2004 | journal = Drug Discov. Today | volume = 10 | issue = 11 | pages = 739–42 |date=June 2005 | pmid = 15922927 | doi = 10.1016/S1359-6446(05)03468-9 }}
* {{cite journal | author = Roth BD | title = The discovery and development of atorvastatin, a potent novel hypolipidemic agent | journal = Prog Med Chem | volume = 40 | issue = | pages = 1–22 | year = 2002 | pmid = 12516521 | doi = 10.1016/S0079-6468(08)70080-8 | series = Progress in Medicinal Chemistry | isbn = 978-0-444-51054-9 }}
* {{cite web | url = http://money.cnn.com/magazines/fortune/fortune_archive/2003/01/20/335643/index.htm | title = The $10 Billion Pill Hold the fries, please. Lipitor, the cholesterol-lowering drug, has become the bestselling pharmaceutical in history. Here's how Pfizer did it | author = Simons J | date = 2003-01-20 | work = Fortune | accessdate = 2011-10-26 | archive-date = 2019-09-15 | archive-url = https://web.archive.org/web/20190915053943/https://money.cnn.com/magazines/fortune/fortune_archive/2003/01/20/335643/index.htm | dead-url = no }}
* {{cite web | url = http://www.oralchelation.net/data/Cholesterol/data11d.htm | title = The Birth of a Blockbuster: Lipitor's Route out of the Lab | author = Winslow R | date = 2000-01-24 | work = [[The_Wall_Street_Journal|The Wall Street Journal]] | accessdate = 2011-10-26 | archive-date = 2013-09-05 | archive-url = https://web.archive.org/web/20130905122745/http://www.oralchelation.net/data/Cholesterol/data11d.htm | dead-url = yes }}
* {{cite web | url = http://www.scienceblog.com/community/older/2003/C/2003363.html | title = Ann Arbor chemist wins national award for drug discovery | author =  | date = 2003-03-01 | work = ScienceBlog | publisher = American Chemical Society | accessdate = 2011-10-26 | archive-url = https://web.archive.org/web/20110614120758/http://www.scienceblog.com/community/older/2003/C/2003363.html | archive-date = 2011-06-14 | dead-url = yes }}
* {{cite web | url = http://blog.wired.com/wiredscience/2008/08/meet-the-guy-wh.html | title = Meet the Guy Who Invented Lipitor | author = Rowe A | date = 2008-08-20 | work = Wired Science | publisher = Wired.com | accessdate = 2011-10-26 | archive-date = 2009-04-10 | archive-url = https://web.archive.org/web/20090410064655/http://blog.wired.com/wiredscience/2008/08/meet-the-guy-wh.html | dead-url = no }}
* {{cite web | url = http://www.medicalnewstoday.com/articles/118387.php | title = Chemical Society To Honor 'Heroes Of Chemistry' During National Meeting | author = Bernstein M | date = 2008-08-16 | publisher = Medical News Today | accessdate = 2011-10-26 | archive-date = 2009-07-03 | archive-url = https://web.archive.org/web/20090703093719/http://www.medicalnewstoday.com/articles/118387.php | dead-url = yes }}
* {{cite web | url = http://chemport.ipe.ac.cn/cgi-bin/chemport/getfiler.cgi?ID=wNidBpcIilyqFodh0jdbIG8so6dfsexvMYICS9WHsn4BeK66YvCg8oTB4mbqO6mN&VER=E | title = Bruce D. Roth, Pfizer Inc, USA | author = He L | date = 2003-09-27 | work =  | publisher = Chinese Academy of Sciences·Institute of Process Engineering | accessdate = 2011-10-26 | archive-url = https://web.archive.org/web/20110719094845/http://chemport.ipe.ac.cn/cgi-bin/chemport/getfiler.cgi?ID=wNidBpcIilyqFodh0jdbIG8so6dfsexvMYICS9WHsn4BeK66YvCg8oTB4mbqO6mN&VER=E | archive-date = 2011-07-19 | dead-url = yes }}
{{refend}}

==外部連結==
* [http://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=117 Atorvastatin bound to proteins] {{Wayback|url=http://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=117 |date=20130518053551 }} in the [[Protein_Data_Bank|PDB]]
* [http://www.lipitor.com/ Lipitor.com] {{Wayback|url=http://www.lipitor.com/ |date=20190516095927 }} – manufacturer's site
* [http://www.nlm.nih.gov/medlineplus/druginfo/meds/a600045.html MedlinePlus Drug information: Atorvastatin (Systemic)] {{Wayback|url=http://www.nlm.nih.gov/medlineplus/druginfo/meds/a600045.html |date=20160705111800 }} – information from USP DI Advice for the Patient
* [http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Atorvastatin U.S. National Library of Medicine: Drug Information Portal - Atorvastatin] {{Wayback|url=http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Atorvastatin |date=20100615041609 }}

{{血脂调节剂}}

[[Category:酰替苯胺|Category:酰替苯胺]]
[[Category:二醇|Category:二醇]]
[[Category:有机氟化合物|Category:有机氟化合物]]
[[Category:輝瑞產品|Category:輝瑞產品]]
[[Category:吡咯|Category:吡咯]]
[[Category:他汀类|Category:他汀类]]
[[Category:药物|Category:药物]]